Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010134 | 1.00 | FOLH1 (0.49) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL6010258 | 0.88 | MME (0.49) | FOLH1NAALAD2MMEL3MBTL1 | |
| SCHEMBL6010262 | 0.88 | MME (0.49) | FOLH1NAALAD2MMEL3MBTL1 | |
| SCHEMBL2214359 | 0.85 | FOLH1 (0.55) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10778599 | 0.85 | FOLH1 (0.55) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL2214358 | 0.85 | FOLH1 (0.55) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL11736267 | 0.84 | FOLH1 (0.46) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL11730247 | 0.84 | FOLH1 (0.46) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL10425352 | 0.83 | FOLH1 (0.57) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| Methoxymethane SCHEMBL10782363 | 0.80 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | FOLH1 1267/4885NAALAD2 114/4885SLC7A5 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.